Horizon Pharma PLC

Horizon Pharma PLC
Stock Exchange NASDAQ Stock Market
EPS
$0.26
Market Cap
$4.5 B
Shares Outstanding
184.88 M
Public Float
167.33 M

Profile

Address
Connaught House
Dublin Dublin 4
Ireland
Employees -
Website http://www.horizontherapeutics.com
Updated 07/08/2019
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.

Financials

View All

Timothy P. Walbert
Chairman, President & Chief Executive Officer
James Samuel Shannon
Independent Director